Juntendo University   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Tokyo Japan (1946)

Organization Overview

First Clinical Trial
2004
NCT00144144
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Chieko Hamada | Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine | Department of Respiratory medicine, Juntendo University | Junten Bio Co., Ltd. | Juntendo University | Juntendo University Advanced Research Institute for Health Science | Juntendo University Graduate School of Medicine | Juntendo University Hospital | Juntendo University School of Medicine | Juntendo University School of Medicine, Dept. of Endocrinology and Metabolism | Juntenndo University Hospital | Katsumi Miyauchi | Professor of Medicine, Department of Cardiovascular Medicine, Juntendo University School of Medicine | Professor of Medicine, Department of Nephrology, Juntendo University Graduate School of Medicine

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Coronary Syndrome (Phase 4)

Atherosclerosis (Phase 4)

Coronary Artery Disease (Phase 4)

Coronary Disease (Phase 4)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Duodenal Ulcer (Phase 3)

Esophagitis (Phase 3)

Esophagitis, Peptic (Phase 3)

Gastroesophageal Reflux (Phase 3)

Hypercholesterolemia (Phase 4)

Hypertension (Phase 4)

Lung Diseases (Phase 3)

Lung Diseases, Obstructive (Phase 3)

Myocardial Ischemia (Phase 4)

Pancreatic Neoplasms (Phase 2)

Pulmonary Disease, Chronic Obstructive (Phase 3)

Stomach Ulcer (Phase 3)

Ulcer (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 15
  • # of Trial APIs: 30